Despite the efficacy of antiestrogens in breast cancer prevention, there is an urgent need to develop safer and more effective chemopreventive strategies which could also inhibit the development of estrogen receptor negative tumors which are more aggressive and associated with a shorter survival. Here, ESR1 is linked to breast carcinoma.